FLGT vs. VCYT, HTFL, CELC, ADUS, LFST, PGNY, ARDT, PACS, NHC, and VRDN
Should you be buying Fulgent Genetics stock or one of its competitors? The main competitors of Fulgent Genetics include Veracyte (VCYT), Heartflow (HTFL), Celcuity (CELC), Addus HomeCare (ADUS), LifeStance Health Group (LFST), Progyny (PGNY), Ardent Health (ARDT), PACS Group (PACS), National HealthCare (NHC), and Viridian Therapeutics (VRDN). These companies are all part of the "healthcare" industry.
Fulgent Genetics vs. Its Competitors
Veracyte (NASDAQ:VCYT) and Fulgent Genetics (NASDAQ:FLGT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.
Veracyte has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.
Veracyte has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.
Veracyte presently has a consensus price target of $40.90, indicating a potential upside of 34.59%. Fulgent Genetics has a consensus price target of $25.33, indicating a potential upside of 13.81%. Given Veracyte's stronger consensus rating and higher probable upside, equities analysts clearly believe Veracyte is more favorable than Fulgent Genetics.
Veracyte has a net margin of 5.50% compared to Fulgent Genetics' net margin of -16.83%. Veracyte's return on equity of 6.07% beat Fulgent Genetics' return on equity.
In the previous week, Veracyte had 8 more articles in the media than Fulgent Genetics. MarketBeat recorded 16 mentions for Veracyte and 8 mentions for Fulgent Genetics. Veracyte's average media sentiment score of 0.94 beat Fulgent Genetics' score of 0.20 indicating that Veracyte is being referred to more favorably in the media.
48.1% of Fulgent Genetics shares are owned by institutional investors. 1.4% of Veracyte shares are owned by company insiders. Comparatively, 31.8% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Veracyte beats Fulgent Genetics on 14 of the 16 factors compared between the two stocks.
Get Fulgent Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FLGT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FLGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fulgent Genetics Competitors List
Related Companies and Tools
This page (NASDAQ:FLGT) was last updated on 8/29/2025 by MarketBeat.com Staff
MarketBeat All Access